Interacciones de Epoetina alfa
Epoetina alfa (Epogen, Procrit, Retacrit) tiene 249 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 1; moderadas: 89; leves: 159; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.
Interacciones según la etiqueta
Interacciones graves (1)
…erythropoietin protein drugs [see Warnings and Precautions ( 5.6 )] Serious allergic reactions to Epogen [see Warnings and Precautions ( 5.7 )] Epogen from multiple-dose vials contains benzyl alcohol and is contraindicated in: Neonates, infants, pregnant women, and lactating women [see Warnings and Precautions ( 5.9 ), Use in Specific Populations ( 8.1 , 8.2 , 8.4 )] . (etiqueta de Epoetina alfa, Contraindicaciones)
Interacciones moderadas (89)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Patients receiving Epogen may require increased anticoagulation with heparin to prevent clotting of the extracorporeal circuit during hemodialysis. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Patients receiving Epogen may require increased anticoagulation with heparin to prevent clotting of the extracorporeal circuit during hemodialysis. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
- Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Menciones leves (159)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etiqueta de Epoetina alfa, Advertencias y precauciones)
Compruebe Epoetina alfa frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.
Abrir en el verificadorNo es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.